We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from...
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) Nonclinical data showed PBFT02 improved...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1807 | 37.489626556 | 0.482 | 0.7899 | 0.463 | 518769 | 0.62266169 | CS |
4 | 0.0424 | 6.83540222473 | 0.6203 | 0.7899 | 0.451 | 287339 | 0.59483006 | CS |
12 | -0.0093 | -1.38392857143 | 0.672 | 0.8499 | 0.451 | 270318 | 0.63219892 | CS |
26 | -0.4673 | -41.3539823009 | 1.13 | 1.33 | 0.451 | 235790 | 0.7321959 | CS |
52 | 0.0613 | 10.1928832724 | 0.6014 | 1.79 | 0.451 | 352361 | 0.9535826 | CS |
156 | -6.6673 | -90.9590723056 | 7.33 | 7.935 | 0.451 | 307681 | 1.76522371 | CS |
260 | -21.6073 | -97.0242478671 | 22.27 | 38.23 | 0.451 | 304823 | 7.42845253 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions